Expand ASND Menu
ASND MENU

ASND Latest Press Releases

-- September 14, 2026 --

Ascendis Announces Planned $400 Million Share Repurchase Program Globe Newswire 6:00 PM
Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular Diseases Globe Newswire 6:00 PM

-- September 9, 2026 --

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 Globe Newswire 4:01 PM

-- September 8, 2026 --

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference Globe Newswire 4:01 PM

-- September 7, 2026 --

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 Globe Newswire 7:00 AM

-- August 31, 2026 --

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) Globe Newswire 7:00 AM

-- August 25, 2026 --

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon CNP (Navepegritide) at ISDS 2026 Globe Newswire 4:01 PM

-- August 18, 2026 --

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Nave Wet Age-Related Macular Degeneration Patients Globe Newswire 8:00 AM

-- August 13, 2026 --

Ascendis Pharma Reports Second Quarter 2026 Financial Results Globe Newswire 7:30 AM

-- August 6, 2026 --

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 Globe Newswire 4:01 PM
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL Uptake in the U.S. Globe Newswire 8:00 AM

-- June 30, 2026 --

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial Globe Newswire 8:30 AM

-- June 26, 2026 --

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap Globe Newswire 4:01 PM

-- June 25, 2026 --

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 Globe Newswire 4:01 PM

-- June 13, 2026 --

Phase 3 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Globe Newswire 4:00 PM

-- June 11, 2026 --

5-Year Phase 2 Data Show TransCon PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism Globe Newswire 4:01 PM

-- June 8, 2026 --

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 Globe Newswire 4:59 PM

-- May 7, 2026 --

Ascendis Pharma Reports First Quarter 2026 Financial Results Globe Newswire 7:30 AM

-- May 6, 2026 --

New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years Globe Newswire 4:01 PM

-- April 30, 2026 --

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes